dysfunction going haywire. we need trials that test drugs that go after each of these different clusters of symptoms and the underpinning issues. there is good news is there is a new booster shot that is expected to become available mid-september here in the u.s. what do you know about that shot and what is your message about the booster? this is directed to be a five which is the variant that has taken over the world. it has created lots of trouble and we don t have a vaccine for as of yet. nothing even close to can take on the variance. it is so distinct from anything that we had previously. it is good that this will become available at scale and serve as a booster. i hope that we will have data to show strong neutralizing antibodies because that will be essential for working well.
previous vaccines and does it generate those antibodies against the new variants? so that s the sort of data they re looking at. ultimately the sort of data that everybody wants is to say, hey, how does this do in real world populations? when you give it to tens of thousands, hundreds of thousands of people, how is it holding up? that data will be that will take longer to sort of accrue. but the fda as they have done in the past may say, you know what, we know this vaccine, it generates similar neutralizing antibodies as we have seen in the past, we re going to go ahead and authorize it, given what is happening potentially this fall, and how much of these new variants are generating, you know, the new cases. i have to say, a relationship built on data is a very solid foundation. i expect good things from both of you. maybe some rose in there, but mostly sanjay, who is going to be eligible for the data always goes better with rose. fully agree. who is eligible for the
/PRNewswire/ The "North America Bioanalytical Testing Services Market 2021-2031 by Molecule Type, Application, Test Type, Workflow Process, Therapeutic.